Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931080 | 0.84 | CYP1A2 (0.40) | KDM1ASLC6A4SLC6A2SLC6A3MTNR1A | |
| SCHEMBL11403650 | 0.78 | KDM1A (0.45) | KDM1ASLC6A4SLC6A2SLC6A3MTNR1A | |
| SCHEMBL8630503 | 0.71 | PRCP (0.37) | KDM1ACYP2D6CYP2C19 | |
| SCHEMBL10685434 | 0.69 | IDO1 (0.53) | KDM1ASLC6A4SLC6A2SLC6A3MTNR1A | |
| SCHEMBL248440 | 0.64 | SLC6A4 (0.59) | KDM1ASLC6A4SLC6A2SLC6A3MTNR1A | |
| SCHEMBL30477104 | 0.64 | SLC6A4 (0.59) | KDM1ASLC6A4SLC6A2SLC6A3MTNR1A | |
| SCHEMBL10971055 | 0.64 | MTNR1A (0.43) | KDM1ASLC6A4SLC6A2SLC6A3MTNR1A | |
| SCHEMBL4019122 | 0.63 | KDM1A (0.42) | KDM1ASLC6A4SLC6A2SLC6A3MTNR1A | |
| SCHEMBL28764771 | 0.63 | GSK3B (0.48) | KDM1ASLC6A4SLC6A2SLC6A3MTNR1A | |
| SCHEMBL562292 | 0.63 | MTNR1A (0.58) | KDM1ASLC6A4SLC6A2SLC6A3MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249139-A1 | Benzamide 2-hydroxy-3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2008-10-09 | — | — | US | claimed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | claimed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-7645780-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. | 2007-12-20 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7244725-B2 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | ELAN PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249139-A1 | Benzamide 2-hydroxy-3-diaminoalkanes | BACE2, BACE1, APP | KDM1A 1440/4885SLC6A4 3979/4885SLC6A2 3125/4885 |
| US-20040180939-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | KDM1A 1864/4885SLC6A4 4627/4885SLC6A2 4587/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | KDM1A 1069/4885SLC6A4 4623/4885SLC6A2 4703/4885 |
| US-20070293483-A1 | Acetyl 2-hydroxy-1, 3-diaminoalkanes | BACE1, BACE2, APP | KDM1A 1940/4885SLC6A4 4501/4885SLC6A2 4538/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | KDM1A 708/4885SLC6A4 4758/4885SLC6A2 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.